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Dear Editors, 
Chronic active antibody-mediated rejection (caAMR) is a major cause of allograft 
loss after kidney transplantation (1). The BANFF 2013 classification redefined 
caAMR by the presence of donor-specific anti-HLA antibodies (DSA) together with 
immuno-histopathological evidence for active vascular lesions of the endothelium 
(C4d deposits, glomerulitis, peritubular capillaritis) as well as evidence of chronic 
tissue injury (transplant glomerulopathy, peritubular capillary basement membrane 
multilayering or arterial intimal fibrosis) (2,3). Humoral immunity, detected by the 
presence of DSA, and B cells are considered pivotal in the development of caAMR. 
Gosset et al. showed that circulating DSA are responsible for accelerated allograft 
fibrosis independently of acute AMR (1). Recent evidence suggested that B cells 
also mediate chronic allograft rejection independently of DSA (4) and that rituximab, 
a chimeric IgG1-antibody targeting human CD20, impair B-cell regulation of T-cells 
(5-7). However, the efficacy of rituximab in patients with caAMR remains 
controversial (8). 
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We retrospectively analyzed 12 kidney-transplant recipients followed at our 
institution between January 2007 and December 2012 who were diagnosed with 
biopsy-proven caAMR (Table 1). All patients were treated with a regimen of 2 doses 
of rituximab (375 mg/m2) at one week interval, as monotherapy, together with a 
transient increase of 20 mg/day oral prednisone, progressively tapered to 5 mg at 
three months. Peripheral B-cell depletion (<10 B-cells/μl) after rituximab 
administration was confirmed by flow cytometry. In seven out of 12 patients, there 
was a decrease in DSA levels below 2000 mean fluorescence intensity (MFI) 
(Luminex, Austin, TX) or a >75% DSA level decrease after rituximab (Figure1A). 
Serum creatinine and proteinuria levels were not significantly different after rituximab. 
Regarding active antibody-mediated vascular lesions, 4/6 patients with positive C4d 
deposits, 6/8 with peritubular capillaritis and 3/4 with glomerulitis, had a decrease in 
the activity score at 1-year post rituximab (Figure 1B). However, chronic histological 
lesions did not improve one year after rituximab (Figure 1C). We further analyzed 
clinical responders defined as patients who improved or maintained stable kidney 
function at 12 months post-rituximab (<20% change of the baseline creatinine) with a 
decrease of DSA titers below 2000 MFI or >75% DSA titers decrease. The results 
showed significantly more C4d deposition in patients with persistent DSA before and 
after rituximab (Figure 2A-B), whereas no significant differences were found between 
clinical responders and non-responders regarding capillaritis and glomerulitis (Figure 
2C-D).  
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We performed CD20 and CD45 staining on all kidney allograft biopsies before and 
after rituximab. The results showed a significant reduction of CD20+ B cells in the 
kidney allograft at one-year (Figure 3A-B). Interestingly, the absolute number of 
CD45+ was not changed (Figure 3C-D).  Peripheral B-cell depletion (<10 B-cells/μl) 
was present only in 5/12 patients after one-year and absolute B cell numbers were 
not different between responders and non-responders (data not shown). These 
results demonstrate that CD20+ B-cells were targeted in the kidney allograft, 
although complete long-term depletion was not achieved. 
Evidence for successful management of caAMR is currently lacking. The first 
randomized trial of eculizumab therapy for caAMR failed to show clinically-relevant 
efficacy on kidney function, DSA titers and chronic-active histopathological lesions 
(9). More recently, Moreso et al published a second randomized trial comparing 
patients with transplant glomerulopathy and DSA receiving four cures of intravenous 
immunoglobulins (IVIG) followed by one infusion (375mg/m2) of rituximab compared 
to placebo, but no improvement in histological lesions, DSA titers and kidney 
function was observed (10). Although both studies were underpowered, they 
demonstrated that untreated patients did not improve chronic active histological 
lesions and maintained high-titers DSA.  
Despite the negative results of the two randomized trials, there is some evidence 
suggesting that B cell depletion is important in the management of caAMR. Thus, 
patients highly sensitized or receiving ABO-incompatible transplants were more 
protected against chronic rejection if treated with rituximab (11,12). In the setting of 
acute AMR and intensive immunosuppression regimen, rituximab seems also to be 
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beneficial (5,13-14). In the present series, rituximab administration was associated 
with a reduction in DSA levels and active histopathological lesions in most patients, 
although this did not translate in an improvement of allograft function, which was also 
confirmed by absence of improvement of chronic lesions in 1-year control biopsies. 
In the EudraCT trial, rituximab was administered only once, up to 6 months after that 
the diagnosis was made resulting in no improvement of DSA or histological lesions 
(10). The results of the prospective multicentric randomized trial (NCT00307125), 
aiming to compare the use of rituximab versus placebo for the treatment of de novo 
early DSA in kidney allograft recipients over a 3-year period time, are therefore 
expected with interest. Finally, it must be also emphasized that future protocols 
should consider the possibility to reinfuse rituximab every 6 months as B-cell 
depletion was found to be significantly reduced but not complete one year after 
rituximab. 
The importance of chronic active T cell-mediated rejection in caAMR should not be 
neglected as T helper cells are key in priming B-cells. Earlier studies showed that 
reversal of DSA can be achieved in the absence of a “desensitization regimen”, but 
in general this was associated with some rescue therapy based on tacrolimus and 
mycophenolate mofetil switch and corticosteroids (15,16). Furthermore, allograft 
survival can be significantly improved after de novo DSA detection if levels of 
tacrolimus are maintained above 5.3 ng/ml (17). In our series, patients received 
transiently more oral prednisone, which possibly acted synergistically with rituximab 
against active lesions, although it must be acknowledged that in the absence of an 
untreated control group, the interpretation of the data must be taken with caution.  
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Tocilizumab and C1-inhibitor, have also been studied for caAMR. Thirty-six patients 
who were refractory to rituximab and IVIG treatment, received tocilizumab, an anti–
IL-6 receptor monoclonal antibody, as rescue therapy, which resulted in reduction in 
DSA titers and in stabilization of allograft function at 2-years (18). Because rituximab 
depletes CD20+ precursor B cells and tocilizumab disrupts the IL-6 supplying niches 
important for Th1/Tfollicular differentiation and long-lived plasma cells, a synergic 
beneficial action of both antibodies could hypothesized as in Castleman’s disease 
(19). Recently, plasma-derived human C1-inhibitor (20UI/kg/twice weekly), an 
inhibitor which targets the classical complement pathway was successfully 
administered for caAMR prevention in highly sensitized patients (20,21). Thus, in the 
future, non-responders to rituximab and/or IVIG may be candidates for combination 
therapy of B cell depleting agents with complement inhibitors or tocilizumab.  
At our center, we do not perform routine protocol biopsies, so that we did not have 
the possibility to select well-matched controls. Even if most patients responded to 
rituximab, active lesions, B cells and in some cases DSA remained present. This 
was also reported by Gupta et al. who targeted B cells using a combination of 
rituximab, IVIG and bortezomib (22), showing that 48% of the patients with late AMR 
were non-responders (22). In the future, more detailed analysis is warranted on the 
potential relationship between DSA, mean fluorescence intensity, HLA types (IgG-
IgM-IgA), sub-classes (IgG 1/2/3/4), HLA class I or II specificity, epitope specificity, 
complement binding (C1q) DSA ability and clinical responses to rituximab. Moreover, 
distinctions between patients with preexisting DSA and de novo DSA would also be 
interesting (23). Overall, it would be important to better define which transplant 
recipients can benefit from rituximab, alone or in combination with other therapies.  
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Table 1 
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Patient’s clinical characteristics. Abbreviation: MMF, mycophenolate mofetil; Pred, 
prednisone; Tac, tacrolimus; Csa, ciclosporine; SRL sirolimus.  TX- transplantation 
date. DSA, donor-specific antibodies, RTX, rituximab, ACR acute cellular rejection.  
Figure 1 
(A) Mean fluorescence intensity (MFI) of de novo class I and II donor-specific 
antibodies (DSA) before and 12 months after rituximab. (B)  Active histological 
lesions including capillary C4d deposits and microvascular inflammation score 
calculated as the combination score of glomerulitis (g) and peritubular capillaritis 
(ptc). (C) Chronic histopathological lesions including chronic glomerulopathy score, 
peritubular capillary (PTC) lamellation score and chronic arteriopathy score. All renal 
biopsies were evaluated by the same experienced pathologist. Two-tailed student t 
tests were used. Mean and standard deviations are shown. * P value < 0.05. 
Figure 2 
(A) Representative CD20 staining. (B) Allograft CD20 positive cells were stained, 
slides were scanned (Zeiss, Oberkochen, Germany) and cells were counted (XX 
software) before and one year after rituximab. (C) Representative CD45 staining. (D) 
Allograft CD45 positive cells were stained, slides were scanned and cells were 
counted before and one year after rituximab. Immunohistochemistry was performed 
on paraffin-fixed tissue for mouse anti-human CD20 (1/400, clone L26, 
Novocastra/Leica, Wetzlar, Germany), and mouse anti-human CD45 (1/1000, clone 
2B11, DAKO, Ely, UK) with automat (Ventana) per our clinical standardized protocol. 
The slides were thereafter scanned (Mirax, Zeiss, Oberkochen, Germany) and cells 
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were quantified using the DIH Image analysis software and the measure-stained-
cells Algorithm (Slidepath software, Leica, Wetzlar, Germany). ** Pvalue < 0.01. 
Figure 3 
(A) C4d deposition score was compared in clinical responders and non-responders 
before (A) and 12 months after rituximab. (B) The combined peritubular capilaritis 
and glomerulitis score was assessed in both group before (C) and 12 months after 
(D) rituximab. * P value < 0.05. ** P value < 0.01. 
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